# Fluorescence Endoscopy of Esophageal Carcinoma

> **NCT03558724** · PHASE1 · TERMINATED · sponsor: **University Medical Center Groningen** · enrollment: 25 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Bevacizumab-IRDye800CW
- **DEVICE:** Molecular Fluorescence Endoscopy platform

## Key facts

- **NCT ID:** NCT03558724
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-29
- **Primary completion:** 2022-10-11
- **Final completion:** 2022-10-11
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Dose-escalation was finished, but no clear correlation between fluorescence and tumor grade was established
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03558724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03558724, "Fluorescence Endoscopy of Esophageal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03558724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*